Francesca Lawson

TL;DR: The use of semuloparin or a pharmaceutically acceptable salt thereof for the extended prevention of a mortality and/or morbidity event, more specifically venous thromboembolism and death, in a patient having undergone hip fracture surgery is described in this paper.

TL;DR: In this article, an ultra-low molecular weight heparin with an average molecular weight of 2000 to 3000 Daltons, with an anti-FXa activity of about 60 U/mg and anti-FIIa activity, was used as an antithrombotic agent for the prophylaxis of venous thromboembolism in cancer patients.

TL;DR: The use of semuloparin or a pharmaceutically acceptable salt thereof for the prevention of a mortality and/or morbidity event, more specifically venous thromboembolism and death, in a patient undergoing major orthopaedic surgery, such as hip replacement, knee replacement or hip fracture surgery, was proposed in this article.